✦ LIBER ✦

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

✍ Scribed by John R Mackey; Miguel Martin; Tadeusz Pienkowski; Janusz Rolski; Jean-Paul Guastalla; Amer Sami; John Glaspy; Eva Juhos; Andrew Wardley; Tommy Fornander; John Hainsworth; Robert Coleman; Manuel R Modiano; Jeferson Vinholes; Tamas Pinter; Álvaro Rodríguez-Lescure; Bruce Colwell; Pierre Whitlock; Louise Provencher; Kara Laing; David Walde; Chris Price; Judith C Hugh; Barrett H Childs; Kimberly Bassi; Mary-Ann Lindsay; Véronique Wilson; Matthieu Rupin; Vincent Houé; Charles Vogel

Book ID: 118262920
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 340 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70525-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant oral etoposide plus cisplatin (

Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)

✍ Fikri Icli; Hakan Akbulut; Handan Onur; Bulent Yalcin; Ahmet Demirkazık; Filiz Ç 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Prognostic and Predictive Value of Tumor

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

✍ Loi, S.; Sirtaine, N.; Piette, F.; Salgado, R.; Viale, G.; Van Eenoo, F.; Rouas, 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 313 KB

Adjuvant chemotherapy and timing of tamo

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB

Randomized phase III trial of adjuvant e

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

✍ Dino Amadori; Rosella Silvestrini; Mario De Lena; Francesco Boccardo; Andrea Roc 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 485 KB

Dose-intensified epirubicin versus stand

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German Adjuvant Breast Cancer Group

✍ Wolfgang Eiermann; Erika Graf; Beyhan Ataseven; Bettina Conrad; Jörn Hilfrich; H 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 665 KB

Seven-Year Follow-Up Assessment of Cardi

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

✍ Zibelman, M.; Goldstein, L.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB